Takeda Partners to Develop Anti-Inflammatory Treatment
Takeda, a Council member, is partnering with ProThera Biologics Inc. to develop a treatment for acute inflammatory conditions.
Under a new global licensing agreement, Takeda will be responsible for the commercial activities and development of the treatment. ProThera is researching a plasma-derived therapy that would replenish naturally occurring proteins that reduce inflammation in the body. Together the companies will explore treatments such as the Inter-alpha Inhibitor Proteins therapy, as well as companion diagnostics to determine the effectiveness of the therapy in a real-world setting.
“We believe ProThera’s expertise in IAIP technology represents a potentially powerful opportunity to explore the untapped potential of plasma in order to address challenging rare and complex diseases,” commented Dr. Chris Morabito, Takeda’s Head of Research and Development, Plasma-Derived Therapies Business Unit. “Leveraging this potent technology using our deep expertise and robust dedicated plasma infrastructure, this collaboration reflects our patient-centered R&D efforts and could represent an important new avenue to deliver meaningful innovation to patient populations in need.”